Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression-Reference-Cited by-同舟云学术

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Published:2018-12-10 Issue:2 Volume:62 Page:448-466
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Yangbing,Yang Jiuling,Aguilar Angelo,McEachern Donna,Przybranowski Sally,Liu Liu,Yang Chao-Yie,Wang Mi,Han Xin,Wang Shaomeng^ORCID

Funder

National Cancer Institute

Oncopia Therapeutics LLC

Rogel Cancer Center, University of Michigan

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00909

Reference36 articles.

1. MDM2, MDMX and p53 in oncogenesis and cancer therapy

2. Awakening guardian angels: drugging the p53 pathway

3. The p53 family in differentiation and tumorigenesis

4. Functions of the MDM2 oncoprotein

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo;European Journal of Medicinal Chemistry;2024-11

2. STRUCTURE-BASED DESIGN OF PROTACS FOR THE DEGRADATION OF SOLUBLE EPOXIDE HYDROLASE;2024-09-05

3. New strategies in soft tissue sarcoma treatment;Journal of Hematology & Oncology;2024-09-02

4. Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics;Biomarker Research;2024-08-21

5. P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds;Biochemical Pharmacology;2024-08